DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20185154

Broad spectrum antibiotic use among in-patients at a hospital in Nairobi, Kenya

Kizito M. Mariita, Harriet A. Chirima, Carol K. Maina

Abstract


Background: Antimicrobial resistance is an increasingly serious threat to global public health. While the use of antibiotics is an important contributing factor, there are gaps regarding this in our region. This study aimed to describe the use of nine broad spectrum antibiotics among in-patients of The Nairobi Hospital (TNH) so as to identify opportunities for quality improvement.

Methods: This was a retrospective review of the use of meropenem, ertapenem, imipenem, cefepime, piperacillin, gentamicin, amikacin, vancomycin and teicoplanin among in-patients of TNH from 1st January 2018 to 31st March 2018. Demographic and clinical data of all in-patients who were prescribed these antibiotics during the study period were retrieved from patient files.

Results: There were 301 study participants with a median age (range) of 30years (1day-74years), of whom 161 (53.5%) were male. More than half of the participants were admitted for less than one week and had at least one co-morbidity. Meropenem was the most commonly prescribed study antibiotic 123 (40.9%) followed by amikacin 89 (29.6%). Respiratory tract infections 125 (41.5%) were the predominant indications. Meropenem had the longest mean duration of administration, 6.5days while the aminoglycosides were administered for a relatively shorter duration of about 4.8days. Cultures were done on 187 (62.1%) patients though it is only samples of 45 patients that grew an organism, E. coli and Klebsiella sp being the most frequently isolated organisms.

Conclusions: There’s a need to strongly intensify implementation of restriction strategies for Meropenem use and introduction of education programs on antimicrobial stewardship targeting all prescribers.


Keywords


Aminoglycosides, Broad-spectrum antibiotics, Meropenem, Resistance

Full Text:

PDF

References


Antimicrobial stewardship: prescribing antibiotics; Guidance and guidelines NICE 2017. Available at: https://www.nice.org.uk/advice/ktt9/chapter/evidence-context.

Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc. 2011;86(11):1113-23.

De Waele JJ, Ravyts M, Depuydt P, Blot SI, Decruyenaere J, Vogelaers D. De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality?. J Critical Care. 2010 Dec 1;25(4):641-6.

Leekha S, Terrell CL, Edson RS. General Principles of Antimicrobial Therapy. InMayo Clin Proc. 2011;86(2):156-67.

English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR). 2017;189. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/656611/ESPAUR_report_2017.pdf.

Bizo PT, Dumitras D, Popa A. Evaluation of restricted antibiotic use in a hospital in Romania. Int J Clin Pharmacy. 2015 Jun 1;37(3):452-6.

Shoaei S, Bagherzadeh A, Haghighi M, Shabani M. Vancomycin and Five Broad-spectrum Antibiotic Utilization Evaluation in an Educational Medical Center in One Year. J Pharmaceuti Care. 2015 Oct 14;2(4):154-61.

Jary F, Kaiser JD, Henon T, Leroy J, Patry I, Blasco G, et a. Appropriate use of carbapenems in the Besançon University Hospital. Med Infectious Dis. 2012 Oct 1;42(10):510-6.

Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943-60.

Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs. 2008;68(6):803-38.

Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027-52.

Muller A, Leroy J, Patry I, Hénon T, Hocquet D, Chirouze C, et al. Appropriateness of aminoglycoside prescriptions in a French university hospital. Medi Infectious Dis. 2016 Sep 1;46(6):308-13.

Vincent JL, Bassetti M, François B, Karam G, Chastre J, Torres A, et al. Advances in antibiotic therapy in the critically ill. Critical Care. 2016 Dec;20(1):133.

Raveh D, Muallem-Zilcha E, Greenberg A, Wiener-Well Y, Schlesinger Y, et al. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem. J Assoc Physicians. 2006 May 8;99(6):397-406.

Salehifar E, Shiva A, Moshayedi M, Kashi TS, Chabra A. Drug use evaluation of Meropenem at a tertiary care university hospital: a report from Northern Iran. J Res Pharmacy Pract. 2015 Oct;4(4):222-5.

Talaat M, Saied T, Kandeel A, El-Ata GA, El-Kholy A, Hafez S, et al. A point prevalence survey of antibiotic use in 18 hospitals in Egypt. Antibiotics. 2014 Sep 10;3(3):450-60.

Ndegwa LK, Katz MA, McCormick K, Nganga Z, Mungai A, Emukule G, et al. Surveillance for respiratory health care–associated infections among inpatients in 3 Kenyan hospitals, 2010-2012. Am J Infect Control. 2014 Sep 1;42(9):985-90.

Holen Ø, Alberg T, Blix HS, Smith I, Neteland MI, Eriksen HM. Broad-spectrum antibiotics in Norwegian hospitals. J Norwegian Med Assoc: Magazine Pract Med, New Series. 2017 Mar;137(5):362-6.

van der Velden LBJ, Tromp M, Bleeker-Rovers CP, Hulscher M, Kullberg BJ, Mouton JW, et al. Non-adherence to antimicrobial treatment guidelines results in more broad-spectrum but not more appropriate therapy. Eur J Clin Microbiol Infect Dis. 2012;31(7):1561-8.

Kim ES, Kim EC, Lee SM, Yang SC, Yoo CG, Kim YW, et al. Bacterial yield from quantitative cultures of bronchoalveolar lavage fluid in patients with pneumonia on antimicrobial therapy. Korean J Internal Med. 2012 Jun;27(2):156.

Álvarez-Lerma F, Alvarez B, Luque P, Ruiz F, Dominguez-Roldan JM, Quintana E, et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Critical Care. 2006 Jun;10(3):R78.